Citations

Mayo Clinic

Showing 10 of 108602 citations.

Reassessing Geographic, Logistical, and Cold Ischemia Cutoffs in Liver Transplantation
Ohara, Stephanie, Macdonough, Elizabeth , Morgan, Paige , Das, Devika , Egbert, Lena K. , Brooks, Abigail , Mathur, Amit K. , Aqel, Bashar , Reddy, Kunam S. , Mathur, Amit , Jadlowiec, Caroline , Das, Devika , Lizaola‐Mayo, Blanca , Morgan, Paige, Aqel, Bashar A. , Jadlowiec, Caroline C.

Progress in Transplantation | April 4, 2023 | Volume: 33 | Issue: 2 | Pages: 168-174

10.1177/15269248231164169 | PMID 37013356 Get It

Introduction Liver acceptance patterns vary significantly between transplant centers. Data pertaining to outcomes of livers declined by local and regional centers and allocated nationally remains limited. Project aim The objective was to compare post-liver transplant outcomes between liver allografts transplanted as a result of national and local-regional allocation. Design This was a retrospective evaluation of 109 nationally allocated liver allografts used for transplant by a single center. Outcomes of nationally allocated grafts were compared to standard allocation grafts (N = 505) during the same period. Results Recipients of nationally allocated grafts had lower model for end stage liver disease scores (17 vs 22, P = .001). Nationally allocated grafts were more likely to be post-cross clamp offers (29.4% vs 13.4%, P = .001) and have longer cold ischemia times (median hours 7.8 vs 5.5, P = .001). Early allograft dysfunction was common (54.1% vs 52.5%, P = .75) and did not impact hospital length of stay (median 5 vs 6 days, P = .89). There were no differences in biliary complications ( P = .11). There were no differences in patient ( P = .88) or graft survival ( P = .35). In a multivariate model, after accounting for differences in cold ischemia time and posttransplant biliary complications, nationally allocated grafts were not associated with increased risk for graft loss (HR 0.9, 95% CI 0.4-1.8). Abnormal liver biopsy findings (33.0%) followed by donor donation after circulatory death status (22.9%) were the most common reasons for decline by local-regional centers. Conclusion Despite longer cold ischemia times, patient and graft survival outcomes remain excellent and comparable to those seen from standard allocation grafts.
The Current Status, Challenges, and Future Potential of Therapeutic Vaccination in Glioblastoma
Neth, Bryan J. , Webb, Mason , Sener, Uğur , Webb, Mason James , Sener, Ugur , Neth, Byran J. , Parney, Ian F.

Pharmaceutics | April 4, 2023 | Volume: 15 | Issue: 4 | Pages: 1134

10.3390/pharmaceutics15041134 | PMID 37111620 Get It

Glioblastoma (GBM) is the most common malignant primary brain tumor and confers a dismal prognosis. With only two FDA-approved therapeutics showing modest survival gains since 2005, there is a great need for the development of other disease-targeted therapies. Due, in part, to the profound immunosuppressive microenvironment seen in GBMs, there has been a broad interest in immunotherapy. In both GBMs and other cancers, therapeutic vaccines have generally yielded limited efficacy, despite their theoretical basis. However, recent results from the DCVax-L trial provide some promise for vaccine therapy in GBMs. There is also the potential that future combination therapies with vaccines and adjuvant immunomodulating agents may greatly enhance antitumor immune responses. Clinicians must remain open to novel therapeutic strategies, such as vaccinations, and carefully await the results of ongoing and future trials. In this review of GBM management, the promise and challenges of immunotherapy with a focus on therapeutic vaccinations are discussed. Additionally, adjuvant therapies, logistical considerations, and future directions are discussed.
Efficacy of Low-Dose Naltrexone and Predictors of Treatment Success or Discontinuation in Fibromyalgia and Other Chronic Pain Conditions: A Fourteen-Year, Enterprise-Wide Retrospective Analysis
Driver, Christine , D’Souza, Ryan S. , Driver, C Noelle, D'Souza, Ryan S , Driver, C. Noelle

Biomedicines | April 4, 2023 | Volume: 11 | Issue: 4 | Pages: 1087

10.3390/biomedicines11041087 | PMID 37189705 Get It

Current pharmacologic treatments may provide limited analgesia in fibromyalgia and other chronic pain disorders. Low-dose naltrexone (LDN) has emerged as a potential analgesic option that has been minimally explored. This study aims to describe current real-world prescribing practices of LDN, to investigate if patients have a perceived benefit of LDN in treating pain symptoms and to identify predictors associated with a perceived benefit or discontinuation of LDN. We evaluated all outpatient prescriptions for LDN prescribed for any pain indication in the Mayo Clinic Enterprise from 1 January 2009 to 10 September 2022. A total of 115 patients were included in the final analysis. The patients were 86% female, had a mean age of 48 ± 16 years, and 61% of prescriptions were for fibromyalgia-related pain. The final daily dose of oral LDN ranged from 0.8 to 9.0 mg, while the most common dose was 4.5 mg once daily. Of patients who reported follow-up data, 65% reported benefit in their pain symptoms while taking LDN. Adverse effects were reported in 11 (11%) patients and 36% discontinued taking LDN by the most recent follow-up. Concomitant analgesic medications were used by 60% of patients and were not associated with perceived benefit nor discontinuation of LDN, including concomitant opioids. LDN is a relatively safe pharmacologic option that may benefit patients with chronic pain conditions and warrants further investigation in a prospective, controlled, and well-powered randomized clinical trial.
Gait Apraxia and Hakim’s Disease: A Historical Review
Milletti, David , Randi, Filippo Tamburini , Hakim, Fernando, Palandri, Giorgio , Palandri, Giorgio , Lanzino, Giuseppe

Biomedicines | April 4, 2023 | Volume: 11 | Issue: 4 | Pages: 1086

10.3390/biomedicines11041086 | PMID 37189704 Get It

In 1965, Prof. Salomón Hakim described, for the first time, a condition characterized by normal pressure hydrocephalus and gait alterations. During the following decades, definitions such as “Frontal Gait”, “Bruns’ Ataxia” and “Gait Apraxia” have been frequently used in pertinent literature in the attempt to best define this peculiar motor disturbance. More recently, gait analysis has further shed light on the typical spatiotemporal gait alterations that characterize this neurological condition, but a clear and shared definition of this motor condition is still lacking. In this historical review, we described the origins of the terms “Gait Apraxia”, “Frontal Gait” and “Bruns’ Ataxia”, starting with the first works of Carl Maria Finkelburg, Fritsch and Hitzig and Steinthal during the second half of the 19th century and ending with Hakim’s studies and his formal definition of idiopathic normal pressure hydrocephalus (iNPH). In the second part of the review, we analyze how and why these definitions of gait have been associated with Hakim’s disease in the literature from 1965 to the present day. The definition of “Gait and Postural Transition Apraxia” is then proposed, but fundamental questions about the nature and mechanisms underlying this condition remain unanswered.
Clinical Information Retrieval: A literature review
Sivarajkumar, Sonish , Mohammad, Haneef Ahamed, Visweswaran, Shyam , Wang, Yanshan , Wang, Yanshan , Oniani, David , Roberts, Kirk E , Hersh, William , Liu, Hongfang , He, Daqing

No container title available | April 3, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2748158/v1 Get It

Abstract Background: Clinical information retrieval (IR) plays a vital role in modern healthcare by facilitating efficient access and analysis of medical literature for clinicians and researchers. This scoping review aims to offer a comprehensive overview of the current state of clinical IR research and identify gaps and potential opportunities for future studies in this field. Objectives: The main objective of this review is to identify and analyze published research on clinical IR, including the methods, techniques, and tools used to retrieve and analyze clinical information from various sources. We aim to provide a comprehensive overview of the current state of clinical IR research and guide future research efforts in this field. Methods: We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and conducted a thorough search of multiple databases, including Ovid Embase, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, Scopus, ACM Digital Library, IEEE Xplore, and Web of Science, from January 1st, 2012, to January 4th, 2023. The screening process involved multiple reviewers, and we included 184 papers for the final review. Results: We conducted a detailed analysis and discussion of various aspects of clinical IR research, including publication year, data sources, methods, techniques, evaluation metrics, shared tasks, and applications. Our analysis revealed key research areas in clinical IR, such as indexing, ranking, and query expansion, and identified opportunities for future research in these areas.
A Phase I Study of a Combination of Liposomal Irinotecan and Veliparib in Solid Tumors
LaRose, Meredith, Connolly, Roisín M. , O’Sullivan, Ciara C. , Velcheti, Vamsidhar , Vilimas, Rasa , Gano, Katherine, Bates, Susan E. , Thomas, Anish , Bates, Susan E , Pommier, Yves G.

The Oncologist | April 3, 2023 | Volume: 28 | Issue: 5 | Pages: 460-e298

10.1093/oncolo/oyad023 | PMID 37010988 Get It

Abstract Background Multiple preclinical studies have shown cytotoxic synergy involving combinations of poly (ADP-ribose) polymerase (PARP) inhibitors and topoisomerase 1 (TOP1) inhibitors, but such combinations have proven too toxic in clinical trials. Liposomal irinotecan (nal-IRI) achieved similar intratumoral exposure with better antitumor activity than the conventional TOP1 inhibitor irinotecan in preclinical models. Tumor targeted delivery of TOP1 inhibitor using nal-IRI and an intermittent schedule of administration of PARP inhibitor may provide a tolerable combination. Methods A phase I study was performed to evaluate the safety and tolerability of escalating doses of nal-IRI and the PARP inhibitor veliparib in patients with solid tumors resistant to standard treatments. Nal-IRI was administered on days 1 and 15 and veliparib on days 5-12 and 19-25 in 28-day cycles. Results Eighteen patients were enrolled across 3 dose levels. Five patients encountered dose–limiting toxicities, including grade 3 diarrhea lasting more than 72 h in 3 patients and 1 patient each with grade 4 diarrhea and grade 3 hyponatremia. The most common grade 3 or 4 toxicities included diarrhea (50% of patients), nausea (16.6%), anorexia, and vomiting (11.1% each) (Table 1). There was no difference in frequencies of adverse events based on UGT1A1*28 status or prior opioid use (Table 1). Conclusion The clinical trial was terminated due to high frequency of unacceptable gastrointestinal toxicities, which precluded dose escalation of veliparib in combination with nal-IRI (ClinicalTrials.gov Identifier: NCT02631733).
A Path to Real-World Evidence in Critical Care Using Open-Source Data Harmonization Tools
Heavner, Smith F. , Anderson, Wesley R., Dasher, Pamela, Weaver, Jeff, Schito, Marco , Kumar, Vishakha K. , Anderson, Wesley, Kashyap, Rahul , Dasher, Pam, Mathé, Ewy A. , Merson, Laura , Guerin, Philippe Jean , Robinson, Matthew L , Nagy, Paul G.

Critical Care Explorations | April 3, 2023 | Volume: 5 | Issue: 4 | Pages: e0893

10.1097/cce.0000000000000893 | PMID 37025303 Get It

COVID-19 highlighted the need for use of real-world data (RWD) in critical care as a near real-time resource for clinical, research, and policy efforts. Analysis of RWD is gaining momentum and can generate important evidence for policy makers and regulators. Extracting high quality RWD from electronic health records (EHRs) requires sophisticated infrastructure and dedicated resources. We sought to customize freely available public tools, supporting all phases of data harmonization, from data quality assessments to de-identification procedures, and generation of robust, data science ready RWD from EHRs. These data are made available to clinicians and researchers through CURE ID, a free platform which facilitates access to case reports of challenging clinical cases and repurposed treatments hosted by the National Center for Advancing Translational Sciences/National Institutes of Health in partnership with the Food and Drug Administration. This commentary describes the partnership, rationale, process, use case, impact in critical care, and future directions for this collaborative effort.
Artificial intelligence and the aging mind
Lee, Jeyeon , Barnard, Leland R , Jones, David T.

Aging | April 3, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.18632/aging.204644 | PMID 37014325 Get It

Evaluation of Plasma Phosphorylated Tau217 for Differentiation Between Alzheimer Disease and Frontotemporal Lobar Degeneration Subtypes Among Patients With Corticobasal Syndrome
Joie, Renaud La , Thijssen, Elisabeth H. , Vento, Stephanie , Tsuei, Torie, Baker, Suzanne L. , Heuer, Hilary W. , Kramer, Joel H. , Ljubenkov, Peter A. , Rabinovici, Gil D. , Rosen, Howie, Staffaroni, Adam M. , Dickerson, Brad C., Huey, Edward D. , Dage, Jeffrey L. , Boxer, Adam L. , Boeve, Brad F, La Joie, Renaud , Rabinovici, Gil D , Dage, Jeffrey L , VandeVrede, Lawren , Asken, Breton M. , Cobigo, Yann , Fonseca, Corrina S. , Rojas, Julio C. , Boeve, Bradley F. , Grossman, Murray , Irwin, David J. , Litvan, Irene , Pantelyat, Alexander , Tartaglia, Maria Carmela

JAMA Neurology | April 3, 2023 | Volume: 80 | Issue: 5 | Pages: 495

10.1001/jamaneurol.2023.0488 | PMID 37010841 Get It

ImportancePlasma phosphorylated tau217 (p-tau217), a biomarker of Alzheimer disease (AD), is of special interest in corticobasal syndrome (CBS) because autopsy studies have revealed AD is the driving neuropathology in up to 40% of cases. This differentiates CBS from other 4-repeat tauopathy (4RT)–associated syndromes, such as progressive supranuclear palsy Richardson syndrome (PSP-RS) and nonfluent primary progressive aphasia (nfvPPA), where underlying frontotemporal lobar degeneration (FTLD) is typically the primary neuropathology.ObjectiveTo validate plasma p-tau217 against positron emission tomography (PET) in 4RT-associated syndromes, especially CBS.Design, Setting, and ParticipantsThis multicohort study with 6, 12, and 24-month follow-up recruited adult participants between January 2011 and September 2020 from 8 tertiary care centers in the 4RT Neuroimaging Initiative (4RTNI). All participants with CBS (n = 113), PSP-RS (n = 121), and nfvPPA (n = 39) were included; other diagnoses were excluded due to rarity (n = 29). Individuals with PET-confirmed AD (n = 54) and PET-negative cognitively normal control individuals (n = 59) were evaluated at University of California San Francisco. Operators were blinded to the cohort.Main Outcome and MeasuresPlasma p-tau217, measured by Meso Scale Discovery electrochemiluminescence, was validated against amyloid-β (Aβ) and flortaucipir (FTP) PET. Imaging analyses used voxel-based morphometry and bayesian linear mixed-effects modeling. Clinical biomarker associations were evaluated using longitudinal mixed-effect modeling.ResultsOf 386 participants, 199 (52%) were female, and the mean (SD) age was 68 (8) years. Plasma p-tau217 was elevated in patients with CBS with positive Aβ PET results (mean [SD], 0.57 [0.43] pg/mL) or FTP PET (mean [SD], 0.75 [0.30] pg/mL) to concentrations comparable to control individuals with AD (mean [SD], 0.72 [0.37]), whereas PSP-RS and nfvPPA showed no increase relative to control. Within CBS, p-tau217 had excellent diagnostic performance with area under the receiver operating characteristic curve (AUC) for Aβ PET of 0.87 (95% CI, 0.76-0.98; P < .001) and FTP PET of 0.93 (95% CI, 0.83-1.00; P < .001). At baseline, individuals with CBS-AD (n = 12), defined by a PET-validated plasma p-tau217 cutoff 0.25 pg/mL or greater, had increased temporoparietal atrophy at baseline compared to individuals with CBS-FTLD (n = 39), whereas longitudinally, individuals with CBS-FTLD had faster brainstem atrophy rates. Individuals with CBS-FTLD also progressed more rapidly on a modified version of the PSP Rating Scale than those with CBS-AD (mean [SD], 3.5 [0.5] vs 0.8 [0.8] points/year; P = .005).Conclusions and RelevanceIn this cohort study, plasma p-tau217 had excellent diagnostic performance for identifying Aβ or FTP PET positivity within CBS with likely underlying AD pathology. Plasma P-tau217 may be a useful and inexpensive biomarker to select patients for CBS clinical trials.
Anesthetic Management and Deep Sedation After Emergence From General Anesthesia: A Retrospective Cohort Study
Deljou, Atousa , Soleimani, Jalal , Martin, David P. , Schroeder, Darrell R. , Schroeder, Darrell , Šprung, Juraj , Weingarten, Toby N.

Anesthesia & Analgesia | April 3, 2023 | Volume: 136 | Issue: 6 | Pages: 1154-1163

10.1213/ane.0000000000006470 | PMID 37010956 Get It

BACKGROUND: Residual deep sedation during anesthesia recovery may predict postoperative complications. We examined the incidence and risk factors for deep sedation after general anesthesia. METHODS: We retrospectively reviewed health records of adults who underwent procedures with general anesthesia and were admitted to the postanesthesia care unit from May 2018 to December 2020. Patients were dichotomized by Richmond Agitation-Sedation Scale (RASS) score: ≤−4 (deeply sedated/unarousable) or ≥−3 (not deeply sedated). Anesthesia risk factors for deep sedation were assessed with multivariable logistic regression. RESULTS: Of the 56,275 patients included, 2003 had a RASS ≤−4 (35.6 [95% CI, 34.1–37.2] cases per 1000 anesthetics administered). On adjusted analyses, the likelihood of a RASS ≤−4 increased when more soluble halogenated anesthetics were used. Compared with desflurane without propofol, the odds ratio (OR [95% CI]) for a RASS ≤−4 was higher with sevoflurane (1.85 [1.45–2.37]) and isoflurane (4.21 [3.29–5.38]) without propofol. Compared with desflurane without propofol, the odds of a RASS ≤−4 further increased with use of desflurane-propofol (2.61 [1.99–3.42]), sevoflurane-propofol (4.20 [3.28–5.39]), isoflurane-propofol (6.39 [4.90–8.34]), and total intravenous anesthesia (2.98 [2.22–3.98]). A RASS ≤−4 was also more likely with the use of dexmedetomidine (2.47 [2.10–2.89]), gabapentinoids (2.17 [1.90–2.48]), and midazolam (1.34 [1.21–1.49]). Deeply sedated patients discharged to general care wards had higher odds of opioid-induced respiratory complications (2.59 [1.32–5.10]) and higher odds of naloxone administration (2.93 [1.42–6.03]). CONCLUSIONS: Likelihood of deep sedation after recovery increased with intraoperative use of halogenated agents with higher solubility and increased further when propofol was concomitantly used. Patients who experience deep sedation during anesthesia recovery have an increased risk of opioid-induced respiratory complications on general care wards. These findings may be useful for tailoring anesthetic management to reduce postoperative oversedation.